Tuesday, March 14, 2017 9:02:42 PM
http://ih.advfn.com/p.php?pid=nmona&article=74081598&symbol=VBIO
Item 1.01. Entry into a Material Definitive Agreement.
On March 9, 2017, Vitality Biopharma, Inc., a Nevada corporation (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company issued to the Purchasers an aggregate of 1,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of US$1.00 per share, for the aggregate purchase price of US$1,500,000.00 (the “Purchase Price”), which closed on March 9, 2017. The Securities Purchase Agreement contains customary representations, warranties, covenants and conditions for agreements of this type. The Company is not required to file a registration statement covering these securities.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM